| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Ostex International, Inc., 2203 Airport Way South, Suite 400, Seattle, WA 98134.
2
John Wayne Cancer Institute, Santa Monica, CA.
3
Orthopedic Research Labs, University of Washington,
Seattle, WA.
a Author for correspondence, Fax 206-292-8625; e-mail dclemens{at}ostex.com
Previous studies have shown that immunoassay of urinary NTx (cross-linked N-telopeptides of type I collagen) provides a responsive index of human bone resorption. Here we report by a sensitive immunoassay that NTx is present in serum and is suppressed appropriately in patients with Paget disease of bone by bisphosphonate antiresorptive therapy. The monoclonal antibody (1H11) developed against urinary NTx was applied in a sensitive chemiluminescence format. Results for human serum and urine showed parallel inhibition curves. The NTx concentrations in paired serum and urine samples from individual patients correlated well when urinary concentrations were normalized to creatinine concentrations (in premenopausal and postmenopausal women and Paget disease patients, r = 0.90, n = 60). The percentage of NTx suppression from baseline values for Paget disease patients on bisphosphonate therapy was similar for serum and urine. Blood samples drawn from bone marrow at the site of Pagetic lesions in three patients with active disease had as much as 10-fold higher concentrations of NTx than did peripheral blood samples drawn at the same time. The latter finding is consistent with other evidence showing that immunoreactive NTx originates directly during the proteolytic cleavage of bone collagen by osteoclasts rather than, e.g., by degradative processes occurring later in the liver and kidney.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  W. DONG, Y. ZHANG, H. LIU, B. GAO, D. LI, and J. YANG Detection of Unsaturated Disaccharides, Pyridinoline, and Hydroxyproline in Urine of Patients with Kashin-Beck Disease: Comparison with Controls in an Endemic Area J Rheumatol, April 1, 2009; 36(4): 816 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. SINGER and D. R. EYRE Using biochemical markers of bone turnover in clinical practice Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Maeno, M. Inaba, S. Okuno, T. Yamakawa, E. Ishimura, and Y. Nishizawa Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients Clin. Chem., December 1, 2005; 51(12): 2312 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Savarino, D. Granchi, E. Cenni, N. Baldini, M. Greco, and A. Giunti Systemic cross-linked N-terminal telopeptide and procollagen I C-terminal extension peptide as markers of bone turnover after total hip arthroplasty J Bone Joint Surg Br, April 1, 2005; 87-B(4): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Ali, L. M. Demers, K. Leitzel, H. A. Harvey, D. Clemens, N. Mallinak, L. Engle, V. Chinchilli, L. Costa, C. Brady, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis Ann. Onc., March 1, 2004; 15(3): 455 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Martini and R. J Wood Relative bioavailability of calcium-rich dietary sources in the elderly Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1345 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jung, M. Lein, K. von Hosslin, B. Brux, D. Schnorr, S. A. Loening, and P. Sinha Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer Clin. Chem., November 1, 2001; 47(11): 2061 - 2063. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brown, R. L. Vessella, P. J. Kostenuik, C. R. Dunstan, P. H. Lange, and E. Corey Serum Osteoprotegerin Levels Are Increased in Patients with Advanced Prostate Cancer Clin. Cancer Res., October 1, 2001; 7(10): 2977 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. O O'Brien, M. Razavi, R. A Henderson, B. Caballero, and K. J Ellis Bone mineral content in girls perinatally infected with HIV Am. J. Clinical Nutrition, April 1, 2001; 73(4): 821 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Garnero, O. Borel, and P. D. Delmas Evaluation of a Fully Automated Serum Assay for C-Terminal Cross-Linking Telopeptide of Type I Collagen in Osteoporosis Clin. Chem., April 1, 2001; 47(4): 694 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Janckila, K. Takahashi, S. Z. Sun, and L. T. Yam Tartrate-resistant Acid Phosphatase Isoform 5b as Serum Marker for Osteoclastic Activity Clin. Chem., January 1, 2001; 47(1): 74 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Prestwood, D. L. Thompson, A. M. Kenny, M. J. Seibel, C. C. Pilbeam, and L. G. Raisz Low Dose Estrogen and Calcium Have an Additive Effect on Bone Resorption in Older Women J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 179 - 183. [Abstract] [Full Text]
|
|
|
|
|
|
C. Rosenquist, C. Fledelius, S. Christgau, B. J. Pedersen, M. Bonde, P. Qvist, and C. Christiansen Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin. Chem., November 1, 1998; 44(11): 2281 - 2289. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
